CANCER GENETICS,INC. (NASDAQ:CGIX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November21, 2017, the Board of Directors (the “Board”) of Cancer Genetics,Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased the size of the Board to nine directors and appointed Dr.Thomas Widmann, age 69, to fill the newly created directorship effective immediately. Dr.Widmann will hold this position until the next annual meeting of the Company’s shareholders or until his successor is elected and qualified, subject to his earlier resignation or removal.
Dr.Thomas F. Widmann is a cardiologist and seasoned life sciences entrepreneur with more than 25 years of biotech experience, and also serves as a Venture Partner at Wellington Partners in Germany. In 1997, he co-founded Actelion Pharmaceuticals, Europe’s largest biopharmaceutical company. As Actelion’s first Chief Executive Officer and Vice Chairman of the Board, he established affiliates in North America, Europe, and Asia. Dr.Widmann has founded several other successful companies including, Hesperion Ltd, an international Contract Research Organization (CRO); Widmann Associates Ltd.; and Auraglobe Ltd., both life-science advisory companies. Previously, he spent nine years at Hoffmann-La Roche (HLR), Basel, leading the international cardiovascular development department, where he brought three cardiovascular drugs to the international markets. He spent six years at the University of California at San Diego (UCSD) as an assistant professor of Medicine. Dr.Widmann studied Medicine and Computer Science at the Universities of Heidelberg and Paris, and holds a Doctorate in Medicine from the University of Heidelberg. He earned his specialization in cardiology at the University of Geneva in Switzerland.
Dr.Widmann will participate in the Company’s standard non-employee director compensation plan, as described in the “Compensation of Directors” section of the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on April21, 2017, which disclosure is incorporated herein by reference.
There are no transactions between Dr.Widmann and the Company that would be reportable under Item 404(a)of Regulation S-K.
The Company will enter into an indemnification agreement with Dr.Widmann (the “Indemnification Agreement”), in the Company’s standard form which has been previously entered into by the Company with each of the Company’s directors and executive officers, the form of which was filed as Exhibit10.7 to the Company’s Registration Statement on FormS-1 filed with the Securities and Exchange Commission on December30, 2011.
Item 7.01. Regulation FD.
On November27, 2017, the Company issued a press release announcing the appointment of Dr.Widmann to its Board of Directors. A copy of the press release is furnished as Exhibit99.1 hereto and shall not be deemed “filed” for the purposes of Section18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
